Skip to main content
Clinical Trials/NCT01121627
NCT01121627
Completed
Not Applicable

Effects of Computer-based Cognitive Training on Gait Function in Individuals With Parkinson Disease

Clalit Health Services1 site in 1 country30 target enrollmentJuly 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
Clalit Health Services
Enrollment
30
Locations
1
Primary Endpoint
Gait Function
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Parkinson's Disease (PD) is a neurodegenerative, progressive illness. It is a multi-system disease that influences not only the motor but also the cognitive and autonomic systems. The main cognitive impairment in individuals with PD is found in executive function (EF). EF is defined as a set of cognitive skills necessary for planning, monitoring and executing sequences of complex activities.

The primary study hypothesis is that computer-based training aimed at improving executive function will have a beneficial effect on gait functions.

Detailed Description

Parkinson Disease (PD) is a neurodegenerative, progressive illness. It is a multi-system disease that influences not only the motor but also the cognitive and autonomic systems. The main cognitive impairment in individuals with PD is found in executive function (EF). EF is defined as a set of cognitive skills necessary for planning, monitoring and executing sequences of complex activities. Previous studies have revealed some relation between cognitive states and physical functions in healthy adults. Few studies have examined the effect of computer-based cognitive training on various populations. These studies showed a positive emotional-cognitive effect in those populations. This type of intervention plan was also applied to PD patients. However, there are no reports on the effect of intentional cognitive training on gait functions. The purpose of the study is to assess whether cognitive training, designed to improve EF ability, can also improve gait function in PD patients.

Registry
clinicaltrials.gov
Start Date
July 2010
End Date
April 2012
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Uzi Milman

Director, Clinical Research Unit, Clalit Health Services, Haifa and Western Galilee District and the Department of Family Medicine, Faculty of Medicine, Technion- Israel Institute of Technology, HAIFA, ISRAEL.

Clalit Health Services

Eligibility Criteria

Inclusion Criteria

  • Idiopathic PD.
  • Aged 50-80, living in north region of Israel.
  • Receive regular medications for PD.
  • Not suffering from irregular cognitive disturbance or MMSE\<
  • Measured 1-3 on the Hoehn \& Yahr scale.
  • Have access to a computer and the ability to operate it.

Exclusion Criteria

  • Brain operation, including DBS transplant.
  • History of orthopedic problems that can impair gait (hip/knee fractures and back problems).
  • Orthopedic operation on lower limbs performed no later than six months prior to the beginning of the study.
  • Unbalanced general health: uncontrolled diabetes or blood pressure, etc.
  • Inability to walk independently.
  • Immunodeficiency diseases, active cancer, ischemic diseases.
  • Vision impairment, partial/full blindness.
  • Having participated in similar research or cognitive assessment during the previous year.
  • Have received cognitive or gait training under physical therapy or other programs.

Outcomes

Primary Outcomes

Gait Function

Time Frame: 18 weeks

At enrollment eligible individuals will undergo a thorough baseline assessment using a predefined set of tests and performance measurements. Within a week after enrollment each individual will receive guided training on the use of the intervention tool, the Attengo™ software program. Thereafter they will train at their homes, at least three times a week, for a period of 12 weeks. Follow up assessments will be performed within a week of the end of the training period and 4 weeks thereafter to check for long-term cognitive and motor changes.

Secondary Outcomes

  • Executive function(18 weeks)
  • Quality of life.(18 weeks)

Study Sites (1)

Loading locations...

Similar Trials